Novel Approaches to Managing Specialty Medications
Novel Approaches to Managing Specialty Medications
The same drug can deliver an additional five months of life for lung cancer patients but only 12 days of life for pancreatic cancer patients. And there are certain specialty therapies to which many patients don’t respond at all. Yet, plan sponsors have paid the same amount for medications like these regardless of the value they provide an individual patient. That is all beginning to change as the industry experiments in ways that better correlate a drug’s price to the value it delivers for the patient.

View this free webcast to hear Adam Kautzner discuss this industry trend, and specifically explain a novel value-driven approach – a combination of indication-based reimbursement capabilities, PBM risk-sharing, and an integrated “whole patient” approach to specialty pharmacy – to improve the cost and care of medications that treat both cancer and inflammatory conditions.

Learning objectives:
  1. Understand the types of outcomes- and value-based contracts that currently exist between payers and manufacturers.
  2. Understand why experiments in outcomes-based contracting have failed in the past, and which current approaches are more likely to succeed.
  3. Learn the best practices that PBMs, payers and specialty pharmacies can apply to ensure that patients receive the best care and the right drugs at the most appropriate cost.

About the speaker:
Dr. Kautzner is Vice President of Drug Trend and Formulary with Express Scripts. He joined Express Scripts in 2008 with increasing leadership responsibilities before his promotion to his current role in 2014. In his current position, Dr. Kautzner is responsible for numerous clinical product initiatives to better serve clients including:
  • All Express Scripts Commercial and Medicare National Formularies
  • All utilization management programs (step therapy, prior authorization, drug quantity management)
  • Medical Benefit Management and Fraud, Waste and Abuse offerings
He received his doctorate of pharmacy degree from the St. Louis College of Pharmacy and is a certified Nuclear Pharmacist through Purdue University.